Open AccessRIPK1 and RIPK3 – emerging targets in cancer?
Author(s) -
Kerem Gurol,
Suraj Shah,
Alexei Degterev
Publication year - 2018
Publication title -
journal of green engineering
Language(s) - English
Resource type - Journals
eISSN - 2245-4586
pISSN - 1904-4720
DOI - 10.13052/2052-8426-2018-03
Subject(s) - necroptosis , ripk1 , cancer , kinase , inflammation , tumor necrosis factor alpha , cancer research , apoptosis , biology , programmed cell death , microbiology and biotechnology , immunology , genetics
Abstract: RIPK1 and RIPK3 are homologous Ser/Thr kinases, which act in concert within the necrosome complexes to initiate a sub-type of regulated necrosis, termed necroptosis. Necroptosis has gradually emerged as a highly clinically relevant form of necrosis, which can be targeted therapeutically. Besides necroptosis, RIPK1 and RIPK3 have been implicated in other pathophysiologically-relevant responses, including regulation of apoptosis and inflammation. More recently, it became evident that RIPK1/RIPK3 pathways may be systematically altered in cancers. Status of these pathways may provide a prognostic value, and therapeutic modulation of RIPK1/RIPK3 signaling may represent a new strategy against various forms of human cancer.